A Man Given 15 Months to Live Got Four Injections. His Latest Brain Scan Came Back Normal.

The Cocktail Report (sound really smart around your friends):

If you or someone you love has ever watched a family member face a devastating diagnosis with few options, this story will hit close to home. A man told he had 12 to 15 months to live is now showing a clean brain scan after four injections of a drug his oncologist had to fight to obtain.

The drug is called Anktiva, and it works by activating natural killer cells (NK cells), specialized immune fighters that patrol your body for cancer and infected tissue. Anktiva is an IL-15 superagonist, meaning it binds to the interleukin-15 receptor and dramatically amplifies NK cell activity, rebooting your immune system's cancer-fighting force.

As we age, these NK cells lose their punch. Anktiva essentially reverses that decline, making it especially relevant for the longevity-focused reader thinking about cancer risk and immune resilience over time.

In ImmunityBio's ongoing Phase 2 trial (QUILT-3.078), Anktiva is paired with an engineered NK cell therapy and bevacizumab, a drug that cuts off tumor blood supply. For a cancer where standard treatment buys patients just 6 to 9 months after recurrence, the results are striking: 19 of 23 enrolled patients remain alive, and median overall survival has not yet been reached.

That last phrase is important. It means researchers can't calculate a midpoint because too few patients have died, which is nearly unheard of in recurrent glioblastoma.

Glioblastoma is the most common malignant brain tumor in adults, and it has seen almost no meaningful survival improvement in over two decades. The fact that a chemotherapy-free immune approach is producing these numbers changes what patients and families should know to ask for.

Here's the complication worth knowing: Anktiva received FDA approval in April 2024, but only for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), a specific form of bladder cancer that doesn't respond to standard treatment. Every glioblastoma patient currently receiving it must go through a special investigational new drug (IND) pathway, a case-by-case authorization that is a significant barrier for people running out of time.

On the safety side, the trial has reported zero cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), two of the most feared complications of immune-based cancer therapies. That profile, combined with the survival signals, is why researchers are calling for continued follow-up and broader access.

This is a story about a treatment that works but isn't widely available. For anyone thinking about cancer risk, immune resilience, and what the next generation of treatments looks like, Anktiva's trajectory is one to follow closely.

Why Should You Care?
Glioblastoma affects tens of thousands of Americans each year, and for most, a diagnosis still feels like a death sentence. Anktiva's Phase 2 results suggest that may finally be changing, if patients know to ask and the approval pathway catches up to the science.

1. ImmunityBio Phase 2 QUILT-3.078 trial results, January 2026 — https://www.clinicaltrialsarena.com/news/immunitybio-immunotherapy-combination-phase-ii-glioblastoma/

2. FDA approval of nogapendekin alfa inbakicept-pmln (Anktiva) for bladder cancer, April 2024 — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer

3. ClinicalTrials.gov QUILT-3.078 study details — https://clinicaltrials.gov/study/NCT06061809

4. LongevityScienceNews YouTube Short, May 2026 — https://youtube.com/shorts/nBt-C9UqRU4